.png)
.png)
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
SHEFFIELD, England, April 20, 2021 /PRNewswire/ -- Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
WCCT GLOBAL (an Altasciences Company) Clinic Expansion
Laval, Quebec, March 23, 2021 – WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants.
Adaptate Biotherapeutics Raises $18 million in Series A2 Funding
• Investment will accelerate the progression of the Company’s lead therapeutic antibody programme towards the clinic and further expand its internal product pipeline • Latest financing takes total funds raised to $34 million
HotHouse BioEngineering and Leaf Expression Systems Sign Plant-Based Expression License Agreement
NORWICH, UK – 13 April 2021: HotHouse BioEngineering (HHBE), which was founded on a body of work from the laboratory of Professor Anne Osbourn FRS OBE of the John Innes Centre, and Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression and production of proteins, today announced a non-exclusive agreement granting HHBE use of Leaf’s expression technology, Hypertrans® for research and development.
R&D Tax Credits – The three most common areas life sciences companies underclaim
We all know how important R&D tax credits are for the Life Sciences, Pharmaceuticals, and Biotech sectors. Most companies in these industries have been claiming since day one, and yet we often encounter companies who are significantly underclaiming. The average benefit for companies in these industries is just over £110k, but Ayming’s average claim for companies in these industries is currently more than £700k, so why is there such a discrepancy?
Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021
Medannex Ltd (Edinburgh) today announced the presentation of new data at the annual meeting of the American Association for Cancer Research (AACR), highlighting the multi-faceted anti-cancer activity of MDX-124 - the company’s proprietary therapeutic antibody.
Cancer Research UK launches new ‘cancer tech accelerator’ programme
Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx
• Collaboration to leverage IONTAS proprietary mammalian display technology • Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology pipeline
The best in AI appointed at Norwich Research Park
Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.
PrecisionLife unveils new spin-out Synomics taking its proven analytics platform into animal and crop health sectors
PrecisionLife Ltd, leaders in combinatorial analytics, today unveils the launch of its new spin-out Synomics Ltd. Synomics will develop and market applications of the PrecisionLife® combinatorial analytics platform for the improvement of the health and yield of livestock and crops in sustainable agriculture and food production. Wheatsheaf Group, PrecisionLife’s lead investor has invested in Synomics, with PrecisionLife retaining a minority equity holding.